ArticleJACC. Advances2026
HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) with preserved ejection fraction (HFpEF) is highly prevalent among adults with type 2 diabetes (T2D) but often remains undiagnosed. The HFpEF-ABA score (based on age, body-mass index and atrial fibrillation) has demonstrated excellent diagnosis performance in patients with unexplained dyspnea but lacks validation for opportunistic screening of HFpEF.
objectivesWe aimed to evaluate the diagnostic and prognostic utility of the HFpEF-ABA score in outpatients with T2D.
methodsWe analyzed 1,125 outpatients with T2D from the prospective, multicenter DIABET-IC cohort. HFpEF diagnosis was based on the European Society of Cardiology guidelines criteria and confirmed by a cardiologist. We evaluated the diagnostic performance of HFpEF-ABA score and its association with 3-year all-cause death, HF hospitalization, and their composite.
resultsHFpEF was confirmed in 190 participants (16.9%). The HFpEF-ABA score yielded an area under the receiver operating characteristic curve of 0.75 (95% CI: 0.71-0.79). Over 3 years, 61 deaths and 23 HF hospitalizations occurred. Per 10-percentage-point increase in HFpEF probability, the risk increased for all-cause death (HR: 1.34; 95% CI: 1.17-1.54), HF hospitalization (HR: 1.16; 95% CI: 0.94-1.43), and the composite endpoint (HR: 1.28; 95% CI: 1.14-1.44). Scores ≥75% identified patients at higher risk of death (HR: 2.40; 95% CI: 1.45-3.97), HF hospitalization (HR: 2.51; 95% CI: 1.10-5.72), and the composite (HR: 2.41; 95% CI: 1.55-3.73).
conclusionsIn ambulatory adults with T2D, the HFpEF-ABA score showed moderate diagnostic discrimination for HFpEF and was associated with adverse clinical outcomes at follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.